CHPA Statement on FDA Advisory Committees Meeting on NSAIDs and Cardiovascular Risks Safety Review

11-02-2014 Business Wire HealthComments (0)

Inflammatory diseasesPharmaceuticalUSA

The Consumer Healthcare Products Association (CHPA) issued the following statement in response to the Food and Drug Administration’s (FDA) Arthritis and Drug Safety and Risk Management advisory committees hearing examining cardiovascular risk data for non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs): “Millions of consumers rely on over-the-counter (OTC) NSAIDs to relieve short-term pain and reduce fever. Each OTC NSAID has been extensively reviewed prior

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top